COMMUNIQUÉS West-GlobeNewswire

Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma
12/12/2024
AUSTIN, Texas and GREENWICH, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO) (“Lumos Pharma” or the “Company”), a clinical stage biopharmaceutical company focused on therapeutics for rare [...]
Revolo Announces New Preclinical Data Supporting Subcutaneous ‘1104 for Atopic Dermatitis and Other Clinical Programs
12/12/2024
In allergen-driven models of atopic dermatitis, subcutaneous (SQ) administration of ‘1104 demonstrated comparable performance to intravenous administration (IV) In multiple preclinical models evaluated in single-dose [...]
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman
12/12/2024
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T ™ ) products [...]
Zymeworks Hosts R&D Day Highlighting Continued Clinical Progress in Oncology Programs and Expansion into Autoimmune and Inflammatory Diseases
12/12/2024
Company on track to deliver five Investigational New Drug (IND) applications as part of ‘5 by 5’ solid tumor strategy 18 months ahead of original target Nomination of ZW209, a novel trispecific T cell engager, as fifth [...]
Scilex Holding Company Announces $17 Million Registered Direct Offering
12/12/2024
PALO ALTO, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing the [...]
Kellner Group Announces Support from Another Former AIM Senior Executive
12/12/2024
Follows Announcement Earlier this Week that Ampligen Co-Founder and Former AIM CEO Agreed to Join Scientific Advisory Board if Kellner Group Nominees Are Elected Kellner Group Reiterates Plan to Revitalize AIM, [...]
Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024
12/12/2024
Data shows strong overall survival, progression-free survival, and durability from novel combination of efti in combination with pembrolizumab in difficult-to-treat head and neck cancer patients with PD-L1 CPS <1 [...]
VITAS® Healthcare Unveils Inpatient Hospice Unit at Franciscan Health Olympia Fields
12/12/2024
The south suburban Chicago home-like facility is expected to serve 500+ patients each year CHICAGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Residents of Olympia Fields and Chicagoland’s surrounding southern suburban [...]
Noom Offers Oral Medications For Weight Loss Starting at $29
12/12/2024
A $29 entry price helps provide accessibility for people pursuing weight loss goals Service includes all features of Noom Med with asynchronous telehealth doctor visits, access to care coordinators, Noom Premium 1:1 [...]
Precede Biosciences Presents a Novel ER Transcriptional Dependency Index at SABCS 2024 Designed to Further Inform Use of Endocrine Therapy from a Simple Blood Test
12/12/2024
Precede Bio’s ER dependency index (PERDI) tests for both ER dependent and ER independent mechanisms of cancer growth, addressing an important unmet need in the field today There are approximately 130,000 people living [...]
BrainsWay Reports Positive Independent Pilot Data on Accelerated Deep TMS Treatment of Alcohol Use Disorder
12/12/2024
BURLINGTON, Mass. and JERUSALEM, Dec. 12, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, [...]
Voting Rights and Shares Capital of the Company
11/12/2024
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Dec. 11, 2024 (GLOBE NEWSWIRE [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
11/12/2024
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 11 déc. 2024 (GLOBE NEWSWIRE) -- Paris, France, le 11 décembre 2024 Place de cotation [...]
MEDIROM Healthcare Technologies Inc. Announces Closing of Public Offering
11/12/2024
TOKYO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM), “MEDIROM”, a holistic healthcare company that operates over 300 wellness salons across Japan and provides healthcare services [...]
Protara Announces Closing of $100 Million Public Offering
11/12/2024
NEW YORK, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the [...]
BriaCell Therapeutics Announces Proposed Public Offering
11/12/2024
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that [...]
BrightSpring Health Services, Inc. Announced Refinancing of Term Loan B
11/12/2024
LOUISVILLE, Ky., Dec. 11, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex [...]
DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old
11/12/2024
Châtillon, France, December 11 th , 2024 DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old DBV and FDA aligned on key study design elements [...]
DBV confirme l’alignement avec la FDA (US) sur la procédure d'approbation accélérée du patch Viaskin® Peanut chez les enfants âgés de 1 à 3 ans
11/12/2024
Châtillon, France, le 11 décembre (22 :05 CEST) 2024 DBV confirme l’alignement avec la FDA (US) sur la procédure d'approbation accélérée du patch Viaskin® Peanut chez les enfants âgés de 1 à 3 ans DBV et la FDA se sont [...]

Pages